Mimivax, Inc
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through- Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide)- Phase 1 in Neuro-Endocrine Tumors (NET)- Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
3
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
1
tools in use
Monthly traffic
104
organic / mo
Sign up free to see all 2 verified contacts at Mimivax, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
- DC
Danielle Casucci
, - · Other
EmailPhone - MC
Michael Ciesielski
Chief Executive Officer · Other
EmailPhone
Showing 2 of 2 verified contacts
Top roles at Mimivax, Inc
2 distinct titles indexed · top 2 shown.
- 1, -
- 1chief executive officer
Sign up to unlock all 2 contacts at Mimivax, Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Mimivax, Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.